Key Highlights

● Sales were $16.6 billion, up 5%, while GAAP EPS was a loss of $0.54.

● A $5.7 billion charge relating to the Terns acquisition drove the accounting loss.

● Keytruda and Keytruda Qlex sales were $8.4 billion, up 5%.

● Non-GAAP EPS guidance was cut to $2.66 to $2.76 from $5.04 to $5.16.

Merck & Co., Inc. (NYSE:MRK), a component of the Dow Jones Industrial Average, reported second-quarter 2026 results on 4 August 2026 that combine healthy sales with a large accounting loss. Sales were $16.6 billion, up 5 per cent, or 4 per cent excluding currency, against $15.8 billion a year earlier. GAAP earnings per share were a loss of $0.54 against a profit of $1.76, and non-GAAP earnings per share were a loss of $0.13 against a profit of $2.13. The cause is acquired research and development charges, chiefly a $5.7 billion charge, or $2.31 per share, relating to the $6.8 billion Terns acquisition. Non-GAAP gross margin was 81.1 per cent against 82.2 per cent. The net loss attributable to Merck was $1.3 billion against net income of $4.4 billion.

Keytruda and the newer franchises

Keytruda and Keytruda Qlex sales were $8.4 billion, up 5 per cent, with the Qlex subcutaneous formulation contributing $463 million. Gardasil and Gardasil 9 vaccine sales were $1.17 billion, up 4 per cent. Among newer products, Winrevair sales rose 75 per cent to $588 million, taking the year-to-date figure to $1.11 billion; Capvaxive rose 42 per cent to $184 million; Welireg rose 67 per cent to $271 million; and Ohtuvayre, acquired with Verona Pharma in October 2025, contributed $204 million. Animal Health segment sales were $1.78 billion, up 8 per cent. A funding agreement with Blackstone reduced research expense by $200 million in the quarter.

Why guidance for earnings fell sharply

Guidance has been reset. Full-year 2026 sales are now expected at $66.3 billion to $67.3 billion, raised from $65.8 billion to $67.0 billion, including roughly one per cent of favourable currency. Non-GAAP earnings per share are now $2.66 to $2.76, against a prior $5.04 to $5.16 and 2025 non-GAAP earnings of $8.98. The reduction reflects a one-time $9.0 billion charge, or $3.62 per share, for the Cidara acquisition, together with the Terns charge. Non-GAAP operating expenses are guided to $42.0 billion to $42.7 billion, up from $36.0 billion to $36.8 billion, and the non-GAAP tax rate to 35.0 to 36.0 per cent from 23.5 to 24.5 per cent. Non-GAAP gross margin is expected near 81 per cent, and the diluted share count near 2.48 billion. Guidance assumes no further significant business development.

Pipeline milestones

Pipeline news was broad. The FDA approved LIPFENDRA (enlicitide), a once-daily oral PCSK9 inhibitor, in July, with placebo-adjusted LDL cholesterol reductions of 56 and 59 per cent at week 24. Sac-TMT met its overall survival and progression-free survival endpoints in advanced or recurrent endometrial cancer. Tulisokibart met its primary endpoint in a Phase 3 ulcerative colitis induction study, although a Phase 2 systemic sclerosis study missed its primary endpoint and will be discontinued. The islatravir and lenacapavir once-weekly oral HIV regimen, developed with Gilead, reported positive Phase 3 results. Keytruda combinations also gained approvals: with Welireg in adjuvant renal cell carcinoma, with Padcev in muscle-invasive bladder cancer and with Trodelvy in first-line PD-L1-positive triple-negative breast cancer. Merck will hold an oncology investor event on 26 October 2026 during the ESMO congress in Madrid.

Separating One-Time Charges From Underlying Keytruda-Led Growth

The headline loss is largely a function of how acquired development costs are expensed, and underlying revenue growth of 4 to 5 per cent is the steadier indicator. Even so, the concentration of sales in Keytruda, the cost of replacing it as exclusivity ends, and the 35 to 36 per cent tax rate are material considerations. Merck lists competition and pricing pressure, healthcare policy, currency, regulatory approval uncertainty, manufacturing delays, patents and litigation among its risks. Dividend information was not included in the release.